The Valdecilla Health Research Institute (IDIVAL) has reached a transfer agreement with the technology company Iridia Inc to license the patent for a DNA encapsulation technology which improves data storage and paves the way for targeted therapies by enabling the delivery of genetic material at the cellular level.
As highlighted by IDIVAL, this approach is “especially promising” for treat diseases that do not respond to traditional treatments and that falls within the field of personalized medicine.
Specifically, this new DNA encapsulation technology, developed by the IDIVAL Nanomedicine team and led by Dr. Mónica López Fanarraga, has “immense potential” in the supply chain security and protection of critical resources.
VERIFY, TRACK AND PREVENT
By embedding coded DNA into products or materials, companies could verify authenticity, track goods throughout the distribution process and prevent counterfeiting. Therefore, at improve data security and traceabilityoffers a disruptive alternative to current storage technologies.
From IDIVAL they have pointed out that “the ability to store and authenticate information securely within the materials of a product itself offers a novel solution to long-standing challenges in supply chain management and resource protection“.
THE ROLE OF IDIVAL IN THE TRANSFER OF TECHNOLOGIES
This agreement also reinforces the role of IDIVAL in the transfer of advanced technologies to the private sectorensuring that scientific discoveries are translated into real solutions, the regional Executive has indicated in a press release.
The IDIVAL Nanomedicine research group, composed of experts in biology, health sciences, physics and chemistryis dedicated to exploring these therapeutic applications and is committed to translational research and clinical innovation.
#IDIVAL #reaches #agreement #improve #data #storage #disease #treatment
